1. Açık Erişim@BUU
  2. İndeksli Yayınlar
  3. Web of Science
Bu öğeden alıntı yapmak, öğeye bağlanmak için bu tanımlayıcıyı kullanınız: http://hdl.handle.net/11452/27330
Tüm üstveri kaydı
Dublin Core AlanıDeğerDil
dc.contributor.authorO'Neil, Bert H.-
dc.date.accessioned2022-06-21T07:24:14Z-
dc.date.available2022-06-21T07:24:14Z-
dc.date.issued2013-03-
dc.identifier.citationKanat, Ö ve O'Neil, BH. (2013). "Metastatic gastric cancer treatment: A little slow but worthy progress". Medical Oncology, 30(1).en_US
dc.identifier.issn1357-0560-
dc.identifier.issn1559-131X-
dc.identifier.urihttps://doi.org/10.1007/s12032-013-0464-4-
dc.identifier.urihttps://link.springer.com/article/10.1007/s12032-013-0464-4-
dc.identifier.urihttp://hdl.handle.net/11452/27330-
dc.description.abstractMetastatic gastric cancer is incurable and remains one of the leading causes of cancer-related deaths around the world. Despite the significant progress in its systemic treatment, metastatic gastric cancer is still a major therapeutic challenge for oncologists. Newer chemotherapy regimens and the addition of molecularly targeted agents to chemotherapy seem to provide better clinical outcomes for patients with metastatic gastric cancer. The objective of this article is to review the current treatment approach for this formidable disease.en_US
dc.language.isoenen_US
dc.publisherHumanaen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectOncologyen_US
dc.subjectGastric canceren_US
dc.subjectChemotherapyen_US
dc.subjectTargeted treatmenten_US
dc.subjectGastroesophageal junction adenocarcinomaen_US
dc.subjectPhase-II trialen_US
dc.subjectChemotherapy-naive patientsen_US
dc.subjectFolinic aciden_US
dc.subjectTargeted therapiesen_US
dc.subject1st-line treatmenten_US
dc.subjectPrognostic modelen_US
dc.subjectPlus cisplatinen_US
dc.subjectDocetaxelen_US
dc.subjectFluorouracilen_US
dc.titleMetastatic gastric cancer treatment: A little slow but worthy progressen_US
dc.typeReviewen_US
dc.identifier.wos000316800800140tr_TR
dc.identifier.scopus2-s2.0-84880626824tr_TR
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı.tr_TR
dc.identifier.volume30tr_TR
dc.identifier.issue1tr_TR
dc.relation.journalMedical Oncologyen_US
dc.contributor.buuauthorKanat, Özkan-
dc.relation.collaborationYurt dışıtr_TR
dc.identifier.pubmed23335104tr_TR
dc.subject.wosOncologyen_US
dc.indexed.wosSCIEen_US
dc.indexed.scopusScopusen_US
dc.indexed.pubmedPubMeden_US
dc.wos.quartileQ3en_US
dc.contributor.scopusid55881548500tr_TR
dc.subject.scopusRamucirumab; Rivoceranib; Lineen_US
dc.subject.emtreeBevacizumaben_US
dc.subject.emtreeCapecitabineen_US
dc.subject.emtreeCetuximaben_US
dc.subject.emtreeCisplatinen_US
dc.subject.emtreeDocetaxelen_US
dc.subject.emtreeDoxorubicinen_US
dc.subject.emtreeEpidermal growth factor receptor 2en_US
dc.subject.emtreeEpirubicinen_US
dc.subject.emtreeEtoposideen_US
dc.subject.emtreeEverolimusen_US
dc.subject.emtreeFluorouracilen_US
dc.subject.emtreeFolinic aciden_US
dc.subject.emtreeGimeracil plus oteracil potassium plus tegafuren_US
dc.subject.emtreeIrinotecanen_US
dc.subject.emtreeMethotrexateen_US
dc.subject.emtreeOxaliplatinen_US
dc.subject.emtreePanitumumaben_US
dc.subject.emtreePhosphatidylinositol 3 kinaseen_US
dc.subject.emtreePlaceboen_US
dc.subject.emtreeTrastuzumaben_US
dc.subject.emtreeVasculotropinen_US
dc.subject.emtreeVasculotropin receptor 1en_US
dc.subject.emtreeVasculotropin receptor 2en_US
dc.subject.emtreeAntineoplastic agenten_US
dc.subject.emtreeAcneen_US
dc.subject.emtreeAnemiaen_US
dc.subject.emtreeAntiangiogenic therapyen_US
dc.subject.emtreeAsiaen_US
dc.subject.emtreeCancer combination chemotherapyen_US
dc.subject.emtreeCancer mortalityen_US
dc.subject.emtreeCancer prognosisen_US
dc.subject.emtreeCancer survivalen_US
dc.subject.emtreeCause of deathen_US
dc.subject.emtreeClinical effectivenessen_US
dc.subject.emtreeContinuous infusionen_US
dc.subject.emtreeDecreased appetiteen_US
dc.subject.emtreeDiarrheaen_US
dc.subject.emtreeDrug dose reductionen_US
dc.subject.emtreeDrug fatalityen_US
dc.subject.emtreeDrug megadoseen_US
dc.subject.emtreeDrug targetingen_US
dc.subject.emtreeDrug tolerabilityen_US
dc.subject.emtreeEsophagus canceren_US
dc.subject.emtreeEuropeen_US
dc.subject.emtreeFebrile neutropeniaen_US
dc.subject.emtreeGene mutationen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeHypokalemiaen_US
dc.subject.emtreeImmunohistochemistryen_US
dc.subject.emtreeMedical decision makingen_US
dc.subject.emtreeMetastasisen_US
dc.subject.emtreeMetastatic stomach canceren_US
dc.subject.emtreeMolecularly targeted therapyen_US
dc.subject.emtreeMonotherapyen_US
dc.subject.emtreeMucosa inflammationen_US
dc.subject.emtreeMulticenter study (topic)en_US
dc.subject.emtreeMultiple cycle treatmenten_US
dc.subject.emtreeNauseaen_US
dc.subject.emtreeNeutropeniaen_US
dc.subject.emtreeOncogene K rasen_US
dc.subject.emtreeOverall survivalen_US
dc.subject.emtreePhase 2 clinical trial (topic)en_US
dc.subject.emtreePhase 3 clinical trial (topic)en_US
dc.subject.emtreePriority journalen_US
dc.subject.emtreeProgression free survivalen_US
dc.subject.emtreeProtein expressionen_US
dc.subject.emtreeQuality of lifeen_US
dc.subject.emtreeRandomized controlled trial (topic)en_US
dc.subject.emtreeRashen_US
dc.subject.emtreeReviewen_US
dc.subject.emtreeStomach canceren_US
dc.subject.emtreeStomach perforationen_US
dc.subject.emtreeStomatitisen_US
dc.subject.emtreeSurvival rateen_US
dc.subject.emtreeSurvival timeen_US
dc.subject.emtreeThromboembolismen_US
dc.subject.emtreeTreatment outcomeen_US
dc.subject.emtreeTreatment responseen_US
dc.subject.emtreeClinical trial (topic)en_US
dc.subject.emtreeDrug delivery systemen_US
dc.subject.emtreePathologyen_US
dc.subject.emtreeStomach tumoren_US
Koleksiyonlarda Görünür:Scopus
Web of Science

Bu öğenin dosyaları:
Bu öğeyle ilişkili dosya bulunmamaktadır.
Kısa Öğe Kaydını Göster İstatistikler


DSpace'deki bütün öğeler, aksi belirtilmedikçe, tüm hakları saklı tutulmak şartıyla telif hakkı ile korunmaktadır.